ArticleInvestigational new drugs2015

Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.

David C Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.